Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. The recent approval of nivolumab in combination with relatlimab (nivolumab-relatlimab) added a third immunotherapy option for first-l...
Saved in:
Main Authors: | Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | EJC Skin Cancer |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611825000060 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical audit of current Helicobacter pylori treatment outcomes in Singapore
by: Tiing Leong Ang, et al.
Published: (2022-09-01) -
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01) -
Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01) -
Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01) -
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01)